Theme watch · accelerating
Medtech stocks to watch · August 2026.
As of 25 August 2026
AI coronary diagnostics re-rated on the 2026-08-13 Q2 print: revenue +48% YoY to $64.1M, FY26 guide lifted to $246–250M from $228–232M, Plaque…
Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM — and the tape has spent six weeks grinding back…
Oncology molecular-profiling re-rate: the 2026-08-05 Q2 beat ($263.7M vs $238.1M est) plus an FY26 guide lift to $1.030–1.040B and positive…
Synthetic-DNA-as-AI-input narrative went vertical: the failed $70 breakout reclaimed and ran to a $105.47 high, +200%+ YTD with 85% of it since…
Autoimmune-diagnostics re-rating on the 2026-08-04 Q2 print: revenue $19.941M vs $17.817M consensus, FY26 guide lifted to $72–75M, adjusted EBITDA…
Signed all-cash takeout: Teledyne agreed on 2026-08-10 to buy Varex at $18.90/share (~$1.1B). The 2026-08-14 close of $18.49 leaves roughly $0.41…
Second-order re-rating: Merck/Moderna's 2026-08-19 Phase 3 INTerpath-001 win — the first positive readout for an individualised neoantigen therapy…
Cloud-genomics platform narrative inflected on the 2026-08-04 Q2 print: net dollar retention 117% vs 107% YoY, FY26 guide raised to $94–96M, and a…
Post-divestiture handheld chemical-detection pure play re-rating on the 2026-08-11 beat-and-raise (revenue $16.07M vs $15.37M est, FY floor lifted…
The MRD story has been overtaken by a live sale process: StreetInsider reported 2026-07-17 that Personalis retained Centerview, TD Securities and…
Post-collapse levered stub has now run past its own sell-side: the 2026-08-21 close of $5.23 sits above the highest of four published 12-month…
Timeline-compression leg extended by broker coverage rather than new data: Needham initiated Buy with a $58 target on 2026-08-17 and price closed…
Busted-growth genomics name; the recovery off the −49% May guide-cut crash has stalled in the low-$60s, below the $74.83 200-day. The confirmed…
"3-mo price move" is the stock's market price change, not a FrontierPicks return. The "3-mo price move" column is one of the three inputs to that score, weighted 20% — not the ranking itself, so rows do not descend in it. A dash means the name did not place in this week’s top-50 momentum scan, so it has no published 3-month figure.
How this page is built
These are the names FrontierPicks covers in the medtech stocks cluster — each with a dated research dossier. Names on the momentum board rank first by a composite momentum score — 1-month price trend 50%, 3-month trend 20% and acceleration 30% — computed arithmetically from daily closes, then the rest of the covered roster by conviction tier. Cluster membership is assigned by a frontier model, currently read as accelerating.
Questions
- What medtech stocks does FrontierPicks cover?
- As of 25 August 2026, the medtech stocks FrontierPicks tracks are led by HTFL, SENS, CAI, TWST, each with a dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest of the covered roster by conviction tier; this is research, not a recommendation.
- Is the medtech stocks theme accelerating or slowing?
- The FrontierPicks model reads this cluster as accelerating as of 25 August 2026. Dated, name-level catalysts rather than tape alone: TEM FDA clearance for Tempus ECG-PH (2026-08-24), PSNL new VA MVP task order (2026-08-20), WGS Genetics in Medicine rapid-genome data (2026-08-24), TWST 52-week high the same day Scorpion Capital disclosed a short (2026-08-19). Status downgrades if the next two weeks bring only index-roundup mentions and no new clearance/contract prints.
- How does FrontierPicks rank medtech stocks?
- Every name links to its dated research dossier. Names on the momentum board rank first by composite momentum score, then the rest of the covered roster by conviction tier. Methodology is open; this is research, not advice.
Related
As of 25 August 2026 · research, not advice.